08/11/2024  17:35:35 Var. +7.20 Volume Denaro08/11/2024 Lettera08/11/2024 Capitalizzazione di mercato Dividend Y. Rapporto P/E
305.20EUR +2.42% 129
Fatturato: 38,675.30
-Quantità in denaro: - -Quantità in lettera: - 163.14 bill.EUR - -

Descrizione business

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Robert Bradway
Consiglio di amministrazione
Peter H. Griffith, Annalisa Pizzarello, Anton Rabushka, Arleen Paulino, Darryl Sleep, David A. Piacquad, David M. Reese, Esteban Santos, Gilles Marrache, Ian Thompson, Jean-Charles Soria, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mark J. Taisey, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Rachna Khosla, Raymond Deshaies, Rob Lenz, Susan Sweeney, Victoria H. Blatter
Consiglio di sorveglianza
Robert A. Bradway, Amy E. Miles, Brian J. Druker, Charles M. Holley Jr., Ellen J. Kullman, Greg C. Garland, Michael V. Drake, R. Sanders Williams, Robert A. Eckert, Ronald D. Sugar, S. Omar Ishrak, Tyler Jacks, Wanda M. Austin
 

Dati aziendali

Name: Amgen Inc.
Indirizzo: One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA
Telefono: +1-805-447-1000
Fax: +1-805-447-1010
E-mail: investor.relations@amgen.com
Internet: www.amgen.com
Industria: Healthcare
Settore: Medical Products
Sub settore: Advanced Medical Devices
Fine dell'anno finanziario: 31/12
Flottante libero: 76.20%
Data dell'IPO: 17/06/1983

Rapporti con gli investitori

Name: -
IR telefono: +1-805-447-1060
IR Fax: -
IR e-mail: investor.relations@amgen.com